MTR-601 for Torticollis
Trial Summary
Do I need to stop taking my current medications for the trial?
The trial requires that you stop using certain medications, such as botulinum toxin and specific drugs that interact with MTR-601, for a specified period before and during the study. However, some treatments for cervical dystonia, like muscle relaxants and benzodiazepines, are allowed if the dose has been stable for at least 3 months.
What evidence supports the effectiveness of the drug MTR-601 for treating torticollis?
Thyrotropin-releasing hormone (TRH), which is related to MTR-601, has shown to improve neurologic recovery after spinal trauma in cats and provided slight to moderate improvements in motor neuron disease symptoms like speech and spasticity in humans. This suggests potential benefits for conditions involving muscle control, like torticollis.12345
What is the purpose of this trial?
Study MTR-601-201 is an 8-week, randomized, placebo-controlled study to examine the safety, tolerability, and efficacy of MTR-601 in participants with cervical dystonia.
Eligibility Criteria
This trial is for adults aged 18-75 with cervical dystonia, experiencing disability and pain. Participants must have been on a stable botulinum toxin treatment for over a year but agree not to use it during the study. They should weigh at least 40 kg with a BMI of ≤35 and commit to effective birth control during and after the trial.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either MTR-601 or placebo daily for 4 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- MTR-601
Find a Clinic Near You
Who Is Running the Clinical Trial?
Motric Bio
Lead Sponsor